摘要:
Aralkylpyridazinone derivatives of the formula I and their physiologically acceptable salts in which R1, R2, R3, R4, R5 and Q have the meanings indicated in claim 1, show inhibition of phosphodiesterase IV and can be employed for the treatment of inflammatory processes and of allergies, asthma and autoimmune disorders.
摘要:
Aralkylpyridazinone derivatives of the formula I and their physiologically acceptable salts in which R1, R2, R3, R4, R5 and Q have the meanings indicated in claim 1, show inhibition of phosphodiesterase IV and can be employed for the treatment of inflammatory processes and of allergies, asthma and autoimmune disorders.
摘要:
Arylalkyl diazinone derivatives of the formula I ##STR1## and their physiologically acceptable salts, in whichR.sup.1, R.sup.2, R.sup.3, R.sup.4, B, Q and X have the meanings indicated in claim 1, exhibit phosphodiesterase IV inhibition and can be employed for the treatment of inflammatory processes and also of allergies, asthma and autoimmune disorders.
摘要:
Benzoyl derivatives of formula (I) and their physiologically acceptable salts and solvates, in which R1, R2, R3, R4, R5 and R6 have the meanings indicated, inhibit phosphodiesterase IV and can be used for the treatment of allergic diseases, asthma, chronic bronchitis, atopic dermatitis, psoriasis and other skin diseases, inflammatory diseases, auto-immune diseases such as rheumatoid arthritis, multiple sclerosis, Crohn's disease, diabetes mellitus or ulcerative colitis, osteoporosis, transplant rejection reactions, cachexia, tumoral growth or tumoral metastases, septicemia, memory defects, atherosclerosis and AIDS.
摘要:
The present invention relates to 5-aminomethylpyrazolo[4,3-d]pyrimidines of the general formula (I) in which the radicals R1 to R6 have the meaning indicated in the text. The compounds show phosphodiesterase V inhibition and can be employed for the treatment of conditions of the cardiovascular system and for the treatment of potency disorders.
摘要:
Pyrazolo[4,3-d]pyrimidines of the formula I and their physiologically acceptable salts, in which R1, R2, R3, R4 and X have the meanings indicated in Claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of disorders of the cardiovascular system and for the treatment and/or therapy of potency disorders.
摘要:
Thienopyrimidines of the formula (I) and their physiologically acceptable salts, in which R1, R2 and X are as defined in claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of illnesses of the cardiovascular system and for the treatment and/or therapy of impotence.
摘要:
Thiadiazinones of the formula I ##STR1## in which R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the meaning given in claim 1, show positively inotropic and vasodilating action and are suitable for combating cardiovascular diseases.
摘要:
The present invention relates to 2-aminomethylthieno[2,3-d]pyrimidines of the general formula (I) in which the radicals R1 to R6 have the meaning indicated in the text. The compounds show phosphodiesterase V inhibition and can be employed for the treatment of conditions of the cardiovascular system and for the treatment of potency disorders.
摘要:
3-Alkoxycarbonyl thiadiazinones of the formula I ##STR1## and physiologically unobjectionable salts thereof, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, Q and n have the meanings described herein, exhibit a positively inotropic action and can be employed for the therapy of cardiac insufficiency.